MorphoSys (HMSE:MOR) - Stock Price, News & Analysis

MOR Stock Overview

Engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. More details

MOR fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Risk Analysis

Earnings have declined by 29% per year over past 5 years

Negative shareholders equity

MorphoSys AG Competitors

Biotest

XTRA:BIO3

€1.4b

Formycon

XTRA:FYB

€830.8m

Heidelberg Pharma

XTRA:HPHA

€104.4m

Gerresheimer

XTRA:GXI

€2.4b

Price History & Performance

Summary of all time highs, changes and price drops for MorphoSys
Historical stock prices
Current Share Price	€67.75
52 Week High	€67.95
52 Week Low	€65.20
Beta	0
11 Month Change	0%
3 Month Change	0.82%
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	1.88%

Recent updates

Shareholder Returns

	MOR	DE Biotechs	DE Market
7D	0%	0.8%	-0.4%
1Y	n/a	-16.7%	7.1%

Return vs Industry: Insufficient data to determine how MOR performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how MOR performed against the German Market.

Price Volatility

Is MOR's price volatile compared to industry and market?
MOR volatility
MOR Average Weekly Movement	0.3%
Biotechs Industry Average Movement	6.3%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	11.0%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: MOR has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine MOR's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1992	464	Arkadius Pichota	www.morphosys.com

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company’s product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren’s disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis.

MorphoSys AG Fundamentals Summary

How do MorphoSys's earnings and revenue compare to its market cap?
MOR fundamental statistics
Market cap	€2.55b
Earnings (TTM)	-€494.62m
Revenue (TTM)	€249.55m

10.2x

P/S Ratio

-5.2x

P/E Ratio

Is MOR overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MOR income statement (TTM)
Revenue	€249.55m
Cost of Revenue	€59.71m
Gross Profit	€189.84m
Other Expenses	€684.46m
Earnings	-€494.62m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-13.13
Gross Margin	76.07%
Net Profit Margin	-198.20%
Debt/Equity Ratio	-518.3%

How did MOR perform over the long term?

See historical performance and comparison

MorphoSys HMSE:MOR Stock Report